ATNM
AMEX · Biotechnology
Actinium Pharmaceuticals Inc
$1.15
-0.01 (-0.86%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.34M | 4.99M | 5.52M |
| Net Income | -1,194,048 | -1,193,914 | -1,096,791 |
| EPS | — | — | — |
| Profit Margin | -22.4% | -23.9% | -19.9% |
| Rev Growth | +5.7% | +20.9% | +5.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 10.51M | 13.17M | 13.40M |
| Total Equity | 16.34M | 19.58M | 16.67M |
| D/E Ratio | 0.64 | 0.67 | 0.80 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -1,875,472 | -1,575,968 | -1,727,883 |
| Free Cash Flow | -941,082 | -691,464 | -912,603 |